AK104 With Chemotherapy as Neoadjuvant and Adjuvant Therapy for Resectable Non-small Cell Lung Cancer

AK104, a tetravalent bispecific antibody targeting PD-1 and CTLA-4, is designed to retain the efficacy benefit of combination of PD-1 and CTLA-4 and improve on the safety profile of the combination therapy. The aim of this study is to evaluate the efficacy and safety of AK104 with chemotherapy as neoadjuvant and adjuvant therapy for patients with resectable stage II-IIIA NSCLC.

Trial Details

NCT ID

NCT05377658

Phase

PHASE2

Sponsor

Henan Cancer Hospital

Status

RECRUITING

Cancer Type

Lung Cancer

Interventions

AK104
Albumin-Bound Paclitaxel
Carboplatin

Locations (sample)

Zhengzhou, Henan, China|34.75778,113.64861

Key Eligibility Criteria

Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
Have previously untreated and pathologically confirmed resectable Stage II-IIIA NSCLC.
Have at least one measurable lesion per RECIST 1.1 assessed by investigator.
Have adequate organ function.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →